House panels seek Ketek documents
Executive Summary
Gearing up for their own investigation of FDA's knowledge of safety issues with Sanofi-Aventis Ketek (telithromycin), the House Energy and Commerce Committee and its Oversight and Investigations Subcommittee seek records from the agency on its premarket review and postmarket surveillance of Ketek. Mindful of charges by Sen. Chuck Grassley, R-Iowa, of FDA and HHS obstructionism during the Senate Finance Committee investigation of the antibiotic's approval, the House panels have specified that the documents be unredacted, except in the case of patient identifiers...
You may also be interested in...
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.